Clinical Trials Logo

Filter by:
NCT ID: NCT02472964 Completed - Breast Cancer Clinical Trials

Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.

HERiTAge
Start date: July 2012
Phase: Phase 3
Study type: Interventional

A multicenter, double-blind, randomized, parallel-group, Phase III study of the efficacy and safety of Hercules( Myl 1401O, Mylan Trastuzumab) plus taxane versus Herceptin® plus taxane as first line therapy in patients with HER2-positive metastatic breast cancer.

NCT ID: NCT02472756 Completed - Clinical trials for Lymphoma, Follicular

Open, Noninterventional Trial of MabThera in Combination With Chemotherapy (CVP, CHOP or FCM) in Patients With Relapsed/Refractory Follicular Lymphoma

Start date: September 2008
Phase: N/A
Study type: Observational

The primary objective of this study is the evaluation of safety and tolerability of rituximab in combination with diferrent chemotherapy regimens. Additional safety data will be gained from prolonged maintenance rituximab treatment.

NCT ID: NCT02468791 Completed - Clinical trials for Rheumatoid Arthritis

MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis

Start date: May 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate biosimilarity between test product MabionCD20® and the reference product - MabThera® (rituximab) and to demonstrate comparative safety and tolerability of a single course of treatment of MabionCD20® and MabThera® in patients with moderate to severe active rheumatoid arthritis.

NCT ID: NCT02467907 Completed - Cervical Cancer Clinical Trials

Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer

Start date: July 28, 2015
Phase: Phase 2
Study type: Interventional

This study is to assess safety as defined by the frequency and severity of gastrointestinal (GI) perforation/fistula, GI-vaginal fistula and genitourinary (GU) fistula in participants treated with bevacizumab 15 milligrams per kilogram (mg/kg) in combination with paclitaxel and carboplatin, all repeated every 3 weeks, for recurrent, persistent or metastatic cervical cancer. In addition, this study will include evaluation of the overall safety profile of bevacizumab in combination with paclitaxel and carboplatin in this setting, assessment of GI perforation/fistula, GI-vaginal fistula and GU fistula events over time, and evaluation of efficacy.

NCT ID: NCT02465567 Completed - COPD Clinical Trials

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

Start date: June 30, 2015
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.

NCT ID: NCT02461589 Completed - Clinical trials for Diabetes Mellitus, Type 2

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Start date: September 21, 2015
Phase: Phase 2
Study type: Interventional

This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes

NCT ID: NCT02461316 Completed - Clinical trials for Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer

Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia

Start date: July 2009
Phase: N/A
Study type: Observational

Evaluation of safety profile and tolerability of MabThera (rituximab) in combination with chemotherapy (fludarabine and cyclophosphamide) in the treatment of Chronic Lymphocytic Leukemia (CLL).

NCT ID: NCT02461290 Completed - Follicular Lymphoma Clinical Trials

Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1

Start date: April 2008
Phase: N/A
Study type: Observational

The primary objective is to evaluate the safety profile and tolerability of rituximab in combination with different chemotherapy regimens.

NCT ID: NCT02453685 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

Start date: August 31, 2015
Phase: Phase 4
Study type: Interventional

This trial is conducted globally. The aim of this trial is to compare stepwise insulin intensification of biphasic insulin aspart (BIAsp) 30 and basal-bolus therapy with insulin glargine and insulin aspart in insulin naïve type 2 diabetic patients inadequately controlled on oral anti-diabetic therapy.

NCT ID: NCT02443467 Completed - Clinical trials for Breast Cancer, Early Breast Cancer

A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer

Start date: July 2006
Phase: N/A
Study type: Observational

This was an open-labeled, multi-center, prospective, non-comparative study of the safety of Herceptin (trastuzumab) used as an adjuvant therapy in patients with early breast cancer who had previously received antracycline therapy before or after surgery.